Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RTA 402 GFR Study in Diabetic CKD
NCT01572610Phase 2Terminated
- Sponsor
- Kyowa Kirin
- Start
- Feb 2012
- Primary completion
- Nov 2013
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of bardoxolone methyl in chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM), sponsored by Kyowa Kirin. Primary endpoints: Glomerular Filtration Rate at 16 weeks and Adverse Event Collection and Assessment at 16 weeks. Started Feb 2012; status: terminated.
02
Drugs
bardoxolone methyl
03
Conditions
chronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01572610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01572610.